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I. INTRODUCTION
It comes as no surprise that certain governmental public health policies raise challenges and
intense scrutiny from its opponents, as well as, from the public. 1 This has been the case with the
Food and Drug Administration's (hereinafter the "FDA") passage of a regulation that excludes
gay men from anonymously donating sperm. 2
In 2004, the FDA announced its regulation on the transfer of Human Cell and Tissue Based
Products ("HCT/P"). 3 Accompanying the regulation, was a draft guidance document that
provided "recommendations for complying with requirements" of the FDA regulation. 4 Among
its recommendations was the exclusion on gay men from anonymously donating sperm, because
of the allegedly high risk of communicable diseases among the Lesbian, Gay, Bisexual, and/or
Transgendered community (hereinafter "LGBT Community"). 5
Not only does this exclusion place a restriction on what gay men can do, it also perpetuates a
stereotype that gay men have a higher rate of communicable diseases than heterosexuals. 6 In
addition, this exclusion is at odds with the FDA's regulation that requires the thorough testing of
donated sperm. 7 Finally, sperm facilities have adopted new techniques that greatly minimize the
spread of communicable diseases during insemination. 8 In light of these factors, there is no

1

Lawrence 0. Goslin, et a!., The Law and Public's Health: A Study ofInfectious Disease Law in the United States, 99
Colum. L. Rev. 59, 94-95 (1999).
2
See generally, Eligibility, Determination for Donors of Human Cells, Tissues and Cellular and Tissue Based
Products, 69 Fed. Reg. 29,786 (May 25, 2005)(codified as 21 C.F.R. pts. 210, 211, 820, 1271) the rule became
effective May 25, 2005 [hereinafter "FDA Regulation"].

'Id.
4
See DRAFT GUIDANCE FOR INDUSTRY: ELIGIBILITY DETERMINATION FOR DONORS OF HUMAN CELLS, TISSUES, AND
CELLULAR AND TISSUE-BASED PRODUCES (HCT/Ps) I, 16-21 (Aug. 8, 2007),
https:l/www,fda.gov/Cber/gdlns/tissdonor.pdf [hereinafter "Draft Guidance Document"].

s Id.
6
See Heterosexual Transmission of HIV-29 States, 1999-2002, 53 Morbidity & Mortality Weekly Rep. 125 (2004)
available at http://www.cdc.gov/mmwr/PDF/wk/mm5306.pdf(last visited Sept. 12, 2012).
7
FDA Regulation, supra note 2.
8
See V. Savasi, eta!., Safety ofSperm Washing and ART outcome in 741 H1V-1-serodiscordant couples, 22 Human
Reproduction 772 (2006).

2

reasonable justification to allow this exclusion to remain as an effective barrier against gay men
seeking to anonymously donate sperm.

a. The Unique Story of Trent Arsenault
The FDA's justification for excluding gay men from anonymously donating sperm is an
example of their overall mission to reduce the risk of communicable diseases in the transfer of
HCT/Ps. 9 However, there are times when their mission detracts them from the actual purpose of
donating sperm: to provide couples with a chance to start a family. The unique story of Trent
Asenault is a perfect example of the FDA imposing its regulation on a situation that does not
require it. 10
Trent Arsenault is a thirty-four (34) year old virgin, who lives in San Francisco and has made
a name for himself as one of the most famous "do it yourself'' ("DIY") sperm donors. 11 The son
of a Pentecostal minister, he grew up in a religious community in Springfield, Missouri. 12 He
eventually made his way to the Bay Area, where he took a job with Hewlett-Packard as a
computer-security engineer. 13 During this time, Trent became more interested in becoming a
sperm donor and adopted a living regiment that would ensure his health and fertility. 14
Trent began to donate his sperm to interested couples; his first time was to a lesbian couple
from his home-town. 15 On December 2006, he met his first donees and established a contract for
the donation of his sperm. After the meeting, Trent donated his sperm and two weeks later, he

9

See FDA Regulation, supra note 2.
See generally, Benjamin Wallace, The Virgin Father, NEW YORK MAG., Feb. 5, 2012, available at
http://nymag.com/news/features/trent-arsenault-2012-2.
11
!d. at l-2.
12 Id
13
!d. at 2, 4.
14
"[Trent] took to monitoring his health and having his blood tested for biomarkers, to gauge the effects of his diet on
testosterone, metabolic function, liver function, enzymes, cholesterol, and vitamin and hormone levels." Trent's house in
Fremont, CA "was far enough from highway exhaust fumes, which caul! lower sperm count, and sheltered by hills on
three sides, blocking out 20 percent of the sky and mitigating his exposure to radiation, another threat to sperm." Id at 410

5.
15

Id at 6.
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received good news that the couple was pregnant. 16 Trent began to get more referrals for his
sperm and decided to set up a website where anyone could review his personal information and
send their request for his donationY By August 2010, Trent had "made around 340 donations to
some 46 recipients," with multiple success stories. 18
Trent's activities reached the ears of the FDA and on April 29, 2009, he received an e-mail
from the FDA inquiring about his activities published on www.trentdonor.com.

19

After

conducting an inspection of Trent's home, the FDA sent an order to cease manufacturing of
HCT/Ps to Trent on November 1, 2010. 20 They charged Trent's "establishment" with violating
Title 21, Code of Federal Regulations, Part 1271 (21 CFR 1271), because he "[did] not provide
adequate protections against the risks of communicable disease transmission."21 As a result, the
FDA demanded that Trent ceased his manufacturing of semen, because he did not follow their
approved protocol of screening HCT/Ps for communicable diseases. 22
Despite Trent maintaining a healthy, fertile, and celibate lifestyle, the FDA considered his
activities to be a risk for the transfer of commuuicable diseases. 23 In Trent's case The FDA
overextended its regulation and restricted a sperm donor, who was not sexually active and did

16
17

Id

!d.; TRENT ARSENAULT, http://www.trentdonor.com.
Benjamin Wallace, supra note 10, at 7.
19
E-mail from Shelley H. Beausoleil, Investigator, Food and Drug Admin., to Trent Arsenault (Apr. 29, 2009) (on file
with recipient) available at http://trentdonor.com/v/logos/fda inspection/correspondence with the fda/FDAsacramento-request-registration-email-trentdonor-29-apr-2009.jpg.htrnl.
20
Letter from Karen Midthun, M.D., Dir., Ctr. for Biologics Evaluations and Research, Food and Drug Admin., to Trent
Arsenault (Nov. l, 2010) (on file with recipient) available at
http://trentdonor.com/vllogos/fda inspection/fda order to cease manufacturing 01-nov-2010/FDA-order-to-ceasemanufacturing-trentdonor-0 1-N ov-20 I 0-pg-1 of5 .jpg.html.
21
In their letter, the FDA charged him with nine (9) counts of violation: I) "failure to test a donor specimen for relevant
communicable diseases;" 2) failure to test specimen for "Human T-cell Lymphotropic Virus types I and II;" 3) failure to
test specimens for genitourinary tract diseases; 4) failure to test specimens or donor seven "days before or after recovery
of semen;" 5) failure to test specimen for diseases associated with xenotransplantation; 6) failure to screen a donor's
eligibility; 7) failure to attach the medical donor eligibility with the donated specimen; 8) failure to keep records of
donations; and 9) failure to have a set of procedures for testing, screening and donating sperm. Id at l.
18

22

Id

23

Benjamin Wallace, supra note 10, at 5, 7.
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not posed any risk of spreading communicable diseases. 24 The FDA's intent to follow its
regulation contrasted with Trent's intention for donating sperm and denied donees access to an
exemplar dono15
Now imagine if instead of Trent, it is a sperm donor facility that takes anonymous donations
from gay men. If the FDA sends them an order to cease manufacturing, they would most likely
adhere to it and refrain from accepting those donations. Unfortunately, this scenario is not hard
to imagine, because the FDA's exclusion empowers the FDA with the means to deprive model
sperm donors the opportunity of helping many couples start a family under pretextual reasons of
the risk of communicable diseases.
The purpose of this Note is to illustrate how the exclusion is an ineffective means of reducing
communicable diseases and that the exclusion should be stricken from the regulation, and
replaced with an alternative, nondiscriminatory. Part I of this Note introduces the FDA
regulation and its exclusion of gay men from anonymously donating sperm. Part II examines the
data the FDA relies on: (1) the four isolated instances of HIV transmission from sperm donors,
none of which address the threat posed by an anonymous gay sperm donor donating under the
current testing provisions; and (2) the recommendations of an advisory board, who they,
themselves, have questioned the accuracy and effectiveness of the particular exclusion. Part III
analyzes a constitutional issue to the exclusion under the Fourteenth Amendment's Equal
Protection Clause. Part III also analyzes the prejudice perpetuated against the LGBT community
through this exclusion. Finally, Part IV of this note advocates the need to revoke the exclusion
and replace it with an alternative nondiscriminatory method.
24

/d. at 7.
"Trent states that his reason for donating his sperm is to help people, "!think I'm doing a good thing," "[h]elping
people. It's compassion, which is a tenet of religion. The official Assemblies of God view on it is that the seed of a man
is between a man and a woman, and if God wants you to have a child, you will, and otherwise you don't have a child.
And if you believe that, it shuts out quite a large group of people wanting to have children. What do you think Jesus
would do?'' !d. at 9-10.
25

5

Although this Note emphasizes that the development of the exclusion derives from the
FDA's actions, it becomes difficult to ascribe an intention upon the exclusion. Even assuming
the absence of discriminatory intent, the exclusion is the product of flawed research findings, and
misguided efforts to pander to social conservative legislators, who disregard the significance of
constitutional protections. Moreover, since its promulgation, proven scientific techniques have
emerged to assure the fitness of all sperm donations, irrespective of their origin. Hence, the
exclusion of gay men from anonymously donating sperm must be abrogated.

II. THE FDA REGULATION AND ITS EXCLUSION ON ANONYMOUS GAY SPERM
DONATION
The FDA regulation was first proposed on September 30, 1999; it was introduced as a rule
relating to donor suitability regarding the transfer ofHCT/P.26 After a protracted period, in which
the FDA entertained various comments, the final rule was issued on May 25, 2004, and went into
effect on May 25, 2005.

27

In conjunction with the final rule, the FDA issued an industry

guidance document that provided a list of recommendations to sperm donor facilities on how to
screen potential donors. 28 The guidance document instructed sperm-donor officials interviewing
potential donors to review their medical records, and "ask questions about the donor's medical
history and relevant social behavior, including risk factors for relevant communicable disease
agents .... " 29 It listed the relevant risk factors for communicable diseases, which included as
number one: "[m]en who have had sex with another man in the proceeding five (5) years"

26

John G. Culhane, Sexual Orientation: Law & Policy: Bad Science. Worse Policy: The Exclusion of Gay Males from
Donor Pools, 24 St. Louis U. Pub. L. Rev. 129, 137 (2005).
27
FDA Regulation, supra note 2.
28
Draft Guidance Document, supra note 4, at 16-21.
29
!d. at 14.
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("MSM"). 30 If these risk factors were revealed during the interview, then it was recommended
that the interviewer consider the potential donor ineligible to donate sperm. 31
Although the FDA received much criticism about this exclusion, it justified its decision by
stating that no new data existed that would warrant a revision of the risk factor. 32 In support of its
position the FDA responded to criticism by stated that:
In response to the comments suggesting that the FDA should allow establishments
to rely on HIV test results alone, or on quarantine and retesting without screening
risk factors, [the] FDA rejects that approach at this time. Although it is reasonable
to expect that more sensitive nucleic acid amplification testing ("NAT") will be
available soon for reproductive tissue donors, even that testing may fail to detect
early stage HIV and other infections, particularly because the level of viremia
may be extremely low in the early stages of infection. Moreover, even the best
test may fail to provide an accurate test result due to human error in running the
test or in linking the test result to the correct donor. Accordingly, FDA believes
that based on the current state of testing and current knowledge about disease
transmission, it is necessary to screen for risk factors as well as to test for diseases
such as HIV 33
In its refusal to amend the regulation and remove the exclusion, the FDA believed it was in line
with its mission statement, which was to protect and advance the public health. 34
As a means to further honor its commitment to the public, the FDA implements a strict
policy of testing all anonymous sperm donors. 35 Under its regulation, the sperm banks must test a
donor's blood seven (7) days in advance of the donation. 36 The FDA requires a quarantine period
of six (6) months, in which the donation is frozen, and after 6 months the donor's blood is
retested for any infection. 37 The FDA's 6-month quarantine on all anonymous donations ensures
that if a recently-infected donor does not test positive at the time of donation, the virus and

Id
Id
FDA Regulation, supra note 2.
33 Id
34
See FDA's Mission Statement, http://www.fda.gov/opacom/morechoices/mission.html (last visited Sept. 8, 2012).
35
21 C.F.R. §§ 1271.80, 1271.85(d)(West 2007).
36
Id
'' Id
3o
31
32
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antibodies would appear at the end of the six months and would be revealed through the second
test. 38 In order to achieve accurate results, the FDA explicitly recommends that sperm banks and
fertility clinics implement new forms of testing that provide earlier detection of HIV and HCV,
usually within days or weeks of infection. 39
Not only does the FDA issue a guidance document to its regulation, it also implements a
safety mechanism in requiring all anonymous sperm donation to be tested twice.40 According to
the FDA, all of these measures are necessary to protect the public from the risk of communicable
diseases. 41
III. THE ABSENCE OF RELIABLE SOURCES TO JUSTIFY THE FDA'S EXCLUION
OFMSMS.

The FDA is the regulating body of the Department of Health and Human Services; it is
established by the Federal Food and Drugs Act of 1906 and is "responsible for regulating food,
drugs, cosmetics, animal feed, biologies, and many other similar products." 42 The FDA's
primary mission is to protect the public from the potential dangers associated with many of these
products, which it attempts to accomplish through its regulations. 43 Before finalizing its
proposals, the FDA seeks the advice of officials and experts in their respected fields in order to
create a comprehensive regulation that addresses all the issues concerning the public's welfare.

38

Luke A. Boso, The Unjust Exclusion of Gay Sperm Donors: Litigation Strategies to End Discrimination in the Gene
Pool, 110 W.Va. L. Rev. 843, 848 (2008) (citing Suitability Determination for Donors of Human and Cellular and
Tissue-Based Products, 64 Fed. Reg. 52,696, 52,706 (proposed Sept. 30, 1999) (to be codified as 21 C.F.R. pts. 210,211,
820, 1271)).
39
Letter from John Givner, Staff Attorney, Lambda Legal to Div. of Dockets Mgmt. Food and Drug Admin. I, 3-4. 4 n.
4 (Aug. 23, 2004), available at http://www.fda.gov/OHRMS/DOCKETS/dailys/04/aug04/083004/04d-0193-c00017voll.pdf.
4
FDA Regulation, supra note 2; see also Draft Guidance Document, supra note 4, at 16-21.
41
FDA Regulation, supra note 2; see also Draft Guidance Document, supra note 4, at 16-21.
42
Luke A. Boso, supra note 38, at 845.
43
FDA Mission Statement, supra note 34.

°
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The FDA relies on a variety of sources when compiling its regulation for the transfer of
HCT/Ps. 44
The FDA excludes MSMs in the hopes of reducing the risk of HIV and AIDS
transmissions. 45 This belief is primarily based upon its reliance on two sources: the first source is
an eighteen year old "Recommendation and Report" issued by the Center for Disease Control
and Prevention ("CDC") entitled "Guidelines for Preventing Transmission of Human
Immunodeficiency Virus Through Transplantation of Human Tissues and Organs" (hereinafter
"CDC Report"). 46 In this report, four instances of HIV transmission from semen donors is
recorded; however, neither one of the instances demonstrates the threat posed by an anonymous
donation from an MSM under the FDA's strict testing provision. 47 The second source 1s a
transcript of a meeting of the "FDA Blood Products Advisory Committee" (hereinafter
"Advisory Committee Meeting") held in December 2001, where a group of medical
professionals debated on the validity of excluding MSMs from anonymous sperm donations. 48
Although the majority of the committee has agreed that the provided data does not accurately
portray the threat of HIV transmission posed by MSMs, the committee has still voted on the
limited information available to them at the meeting. 49 These two sources constitute the primary
information the FDA relies on to justify its exclusion of MSMs from anonymously donating
sperm.
a.

The CDC Report

44

FDA Regulation, supra note 2.
"Id.
46
Ctr. for Disease Control & Prevention, Guidelines for Preventing Transmission of Human Immunodeficiency Virus
through Transplantation of Human Tissues and Organs, 43 Morbidity & Mortality Weekly Rep. l (1994), available at
http:///www.cdc.gov/mmwrhtmV0031670.htm (last visited Sept. 13, 2012) [hereinafter CDC Report].
47
I d. at I: FDA Regulation, supra note 2.
48
See generally Food & Drug Admin., Dep't of Health & Human Servs., Blood Products Advisory Committee 70 [su'th]
Meeting (Dec. 14, 2001), available at http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3817t2.html (last visited Sept.
13, 2012) [hereinafter Advisory Committee Meeting].
49 ld.

9

The FDA relied on the CDC report to justify the exclusion of MSMs. The CDC report
explained whether there was a need for increased federal oversight of transplantation of
HCT/P.

50

It was created after a 1991 investigation revealed several instances of HIV

transmission in recipients that had received an organ or tissue donation. 5 1 Despite the important
need to reduce the risk of HIV transmission, the CDC report was only able to identify four
instances of HIV transmissions, none of which pertained to MSM donations. 52
The first case of HIV transmission showed a human error to be the cause of the transmission,
where a required confirmatory test for HIV was never administered. 53 In the second case, the
facility allowed a period of eight months to elapse between the time the donor was tested for
HIV and the time he donated. 54 The third case resulted from an emergency condition, which
heightened the risk of HIV transmission, because no precautionary testing could be taken. 55
Finally, the fourth case involved an issue regarding the risk of HIV transmission within the
window phase or period of "seroconversion. " 56
In addition to citing instances ofHIV transmission in HCT/P recipients, the CDC report cited
several studies of HIV transmission that were conducted in the 1980s. 57 Through these studies,

° CDC Report, supra note 46, at I.

5

!d.
Id at2.
"ld
54
Id
55
Id
56
Seroconversion is defined as: "the production of antibodies in response to an antigen," Seroconversion Definition,
MERRIAM-WEBSTER DICTIONARY, available at http://www.merriam-webster.com/medical/seroconversion; or "The
change from HIV -negative to HIV-positive status during blood testing. Persons who are HIV-positive are called
seroconverters." Seroconversion Definition, THE FREE-DICTIONARY, available at http://medicaldictionary.thefreedictionary.com/seroconversion.
57
CDC Report, supra note 46, at 15; see also John G. Culhane, supra note 26, at 140 (citing Ctrs. for Disease Control &
Prevention, Current Trends Prevention of Acquired Immune Deficiency Syndrome (AIDS); Report of Inter-Agency
Recommendations, 32 Morbidity & Mortality Weekly Rep. 101-3 (1983), available at
http://www.cdc.gov/mmwr/preview/mmwrhtml/0001257.htru (last visited Sept. 12, 2012); Ctrs. for Disease Control &
Prevention, Provisional Public Health Service Inter-Agency Recommendations for Screening Donated Blood and Plasma
for Antibody to tbe Virus Causing Acquired Immunodeficiency Syndrome, 34 Morbidity & Mortality Weekly Rep. 1-5
(1985), available at http://www.cdc.gov/mmwr/preview/mmwrhtrul/0033029.htm (last visited Sept. 12, 2012); Ctrs. for
Disease Control & Prevention, Epidemiologic Notes and Reports Testing Donors of Organs, Tissues, and Semen for
51
52
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the CDC fortified its recommendation to exclude MSMs. 58 In addition to these early reports, the
CDC report cited their 1988 report that focused on blood and sperm donations. 59 The FDA based
its regulation on the recommendations of the CDC report, which itself relied on isolated
instances of HIV transmission in donor recipients, and CDC reports from the early to late
1980s. 60
b. The FDA Advisory Blood Products Committee Meeting and the Young Men's Survey

The second source the FDA based its decision on was the transcript from the Advisory
Committee Meeting held in December 2001. 61 After the FDA drafted the proposed rule in 1999,
it invited the Blood Products Advisory Committee to review various comments and concerns
regarding the proposed regulation. 62 Among other issues, the Committee focused on the issue of
whether MSMs constituted a risk factor for communicable diseases. 63 In analyzing this question,
the Committee reviewed the data assembled by Dr. Linda Valleroy, an epidemiologist for the
CDC's Division ofHIV-AIDS Prevention. 64
Dr. Valleroy assembled her data in the Young Men's Survey ("YMS"). 65 The study was
conducted in seven U.S. cities beginning in 1993. 66 Based on the results of the survey, Dr.
Valleroy stated that "[ c]ompared to the general population the incidence rates among men who
have sex with men [were] [eighty-seven] 87 to [one hundred ninety three] 193 times higher for
Antibody to Human T-Lymphotropic Virus Typ III/Lymphadenopathy-Associated Virus, 34 Morbidity & Mortality
Weekly Rep. (1985), available at http://www.cdc.gov/mmwr/preview /mmwrhtml/00000547.htm (last visited Sept. 12,
2012)).
58
CDC Report, supra note 46, at 15.
59
John G. Culhane, supra note 4, at 141 (citing Ctrs. for Disease Control & Prevention, Perspectives in Disease
Prevention and Health Promotion, Semen Banking, Organ and Tissue Transplantation, and HIV Antibody Testing, 37
Morbidity & Mortality Weekly Rep. 57-58, 63 (1988), available at
http://www.cdc.gov/mmwr/preview/mmwrhtml/00001037.htm (last visited Sept. 12, 2012)).
60
See generally CDC Report, supra note 46.
61
See generally Advisory Committee Meeting, supra note 48.
62 !d.
63 !d.
64 !d.
65
!d. (citing Linda Valleroy, et al., The Young Men's Survey: Methods ofEstimating HIV Seroprevelance and Risk
Factors among Young Men Who Have Sex with Men, Ill Pub. Health Rep. 138 (1996)).
66
Advisory Committee Meeting, supra note 48.
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HIV. " 67 She based her results on tbe process by which she and her team obtained tbe relevant
data, which was conducted by taking samplings of young men between tbe ages of 15 and 22
who admitted to having sex with men from the periods of 1994 to 1998. 68 The survey was
conducted in Baltimore, Dallas, Los Angeles, Miami, New York City, San Francisco and
Seatt1e. 69 Dr. Valleroy located her subgroup of young men by going to specific venues that were
known to attract young promiscuous men. 70 These venues "were [anything] from parks, beaches,
street locations, restaurants, coffee shops, dance clubs, bars, gyms, [or] any place that young men
who [have] sex with men would go." 71
In order to conduct each sampling, a four-person survey team would park a van modified to
hold two simultaneous interviews near the venues. 72 The team would then target young men
between the ages of 15-22 and asks a series of questions, followed by drawing their blood and
testing it for HIV, Hepatitis B, and Syphilis. 73 At each sampling, tbe team collected the following
data: "(a) the total number of young men who visited the venue; (b) of those counted, tbe number
of young men intercepted and briefly interviewed; (c) the age, race, and county residence of
young men intercepted; (d) of those intercepted, tbe number of young men who were determined
eligible for the first time; and (e) tbe number of young men who enrolled in YMS." 74
Dr. Valleroy's team enrolled three thousand four hundred ninety two (3,492) young men,
which was approximately five hundred (500) young men in each city. 75 The enrollment rate was
around sixty-two percent (62%), which provided the desired data regarding HIV transmission

67

Id
Id
69 Id
7o Id
71 Id
68

72

Linda Valleroy, eta!., supra note 65, at 140.
Advisory Committee Meeting, supra note 48.
74
Linda Valleroy, supra note 65, at 141.
75
Advisory Committee Meeting, supra note 48.

73
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among young men who had sex with men. 76 The data from the survey showed an HIV
prevalence of7.2%, and a hepatitis B prevalence of 10.7%, which was categorized as a very high
prevalence of communicable diseases in a subgroup. 77 Dr. Valleroy provided this data to the
Advisory Committee as a sampling and an illustration of the high rates of communicable
diseases within the entire MSM subgroup. 78
Upon the conclusion of the meeting, the committee casted a vote concerning whether MSMs
should be considered a risk factor in the proposed FDA regulation. 79 The question the committee
asked was "[were] there existing data that identif[ied] subsets of men who [had] sex with other
men, in which the incidence and prevalence rates ofHIV, HBV, and HCV of the subsets [were]
similar to the population at large?" 80 Many of the members expressed concerns over the wording
of the question, and observed that because the only data available was the YMS study, the
answer to the question was a resounding "no."

81

The committee decided to posit a

recommendation to the FDA to request data about the identity of a subgroup of men who have
sex with men, in which the prevalence of communicable diseases was similar to the rate in the
public at large. 82 Despite the recommendation, the FDA in its final rule did not request a study to
be conducted to answer this question; instead, the FDA took as authoritative the answer the
committee gave to the initially proposed question. 83

!d.
/d.
78 !d.
79 !d.
80 ld.
81
The committee attempted to replace the question with another more accurate question, but failed to reach a consensus.
One Committee member, Dr. Stroncek came close to a more accurate question stating that the question should ask if
"[ e]xisting screening questions, laboratory tests and quarantine procedures can be used to identify a subset of men who
had sex with other men in which the prevalence rates ofHIV, HBV, and HCV of the subjects is similar to that of the
public at large." !d.
82 /d.
83
FDA Regulation, supra note 2.
76

77
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The FDA's reliance on the CDC report and the Advisory Committee Meeting to justify their
exclusion is misplaced. The CDC report based its information on four, isolated instances of HIV
transmission and reports that are over twenty-five years old. In turn, the FDA based its decision
and rulings on the YMS study, which over-generalizes the MSM subgroup by applying a study
that focuses on a very specific group within the MSM subgroup to the entire MSM population.
Moreover, the Advisory Committee established by FDA to review the exclusion believed the
YMS study to be too limited to support the exclusion absent a greater scientific review.
c. The "Outdatedness" and Inaccuracy of the Sources Used to JustifY the Exclusion

The FDA's two sources are skewed and inaccurately represent the rate ofHIV and Hepatitis
B transmission among MSMs. The CDC Report does not provide a justifiable explanation as to
why MSMs are excluded from donating sperm and instead relies on a few isolated instances of
HIV transmission and data from over twenty-five year old reports. 84 None of the instances
described in the report concerns a transmission of HIV in the context of frozen sperm donation. 85
In the first case, the donor never received the required HIV test before making his donation. 86
In the second instance, the donation was made eight (8) months after the donor took the HIV test,
which left a large window of time open for the donor to contract the virus. 87 The third case
involved an emergency situation where waiting for the test results was not a viable option (this
would not occur in the context of sperm that is quarantined for 6 months). 88 Finally the fourth
instance involved a window problem, where the donor did not come up positive during testing,
because the test was administered during the time of "seroconversion." 89 Again, the concurrent
FDA requirement to test donors twice, once before the donation and again after the quarantine
84

CDC Report, supra note 46, at 2.
John G. Culhane, supra note 26, at 140.
86
John G. Culhane, supra note 26, at 140 (citing CDC Report, supra note 46, at 2).
87
Id
88
Id
89
Id
85
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period, has reduces

instances of HIV transmissions through donation from occurring again. 90

Given the unique circumstance of the HIV transmission in each of these instances, no data exists
to prove that there is a threat of transmission from an MSM, who has undergone the double
testing and six-month quarantine requirement. 91
In addition to referencing unrelated instances of HIV transmission, the CDC's reliance on
outdated reports does not provide a reasonable justification for the exclusion in today's world. 92
The earliest CDC report is from 1983, while the other two are from 1985. 93 Neither of these
reports gives an in-depth analysis of the actual risk of HIV transmission from an MSM
donation. 94 The CDC's 1988 release entitled "Perspectives in Disease Prevention and Health
Promotion, Semen Banking, Organ and Tissue Transplantation and HIV Antibody Testing" has
come close to giving a justification to the exclusion. 95 However, the release only emphasized the
importance of freezing sperm donations and imposing a quarantine period without specifically
discussing the reasons for the exclusion. 96 Ultimately, the old reports fail to provide an
independent justification as to why the exclusion is a legitimate way to prevent the potential
threat ofHIV transmission in MSM donations. 97
Unlike the CDC Report that never provides a direct or justifiable explanation for the
exclusion, the Advisory Committee Meeting directly addresses the issue by reviewing the data

90 Jd
91Jd
92 Jd
93

The 1985 report is from the time when HIV -antibody testing was introduced to the public health community, and not a
lot of information about HIV was known to the general public. 93 Jd at 141.
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95

Jd
Jd (citing Ctrs. for Disease Control & Prevention, Perspectives in Disease Prevention and Health Promotion, Semen

Banking, Organ and Tissue Transplantation, and HIV Antibody Testing, 37 Morbidity & Mortality Weekly Rep. 57-58,
63 (1988), available at http://www.cdc.gov/mmwr/preview/mmwrhtml/00001037.htm (last visited Sept. 13, 2012)).
96
97
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compiled in the YMS study. 98 However, the data presented in the study creates an inaccurate
illustration ofthe rate of communicable diseases among MSMs.
The study obtained its result from a small subset of MSMs: young men between the ages of
15 and 22 who engaged in sex with men and frequented venues with high rates ofpromiscuity. 99
Dr. Peter Lachenbrach expressed these sentiments at the meeting stating that the study had
"gotten the most active participants in MSM, and that might lead to an upward bias in the rates
[she had] gotten." 100 In response to Dr. Lachenbrach's statement, Dr. Valleroy justified her study
by admitting that there was no plausible way to glean an accurate representation of the rate of
communicable diseases among the MSM population. 101
Mr. Leeland Terriman, Director of the Rainbow Flag Health Services and Sperm Bank in
Oakland, California, also raised concerns about the results from the study. 102 He believed that the
FDA inappropriately applied the results of the study to all gay men, rather than narrowing it
down to the subgroup of young men between the ages of 15 and 22. 103 He stated that applying
sexual habits of young gay men to other gay men in their thirties and forties, or gay men in
monogamous relationships grossly exaggerated the rate of communicable diseases among
MSMs. 104 The YMS study was the only study the Advisory Committee had to determine whether
MSMs posed a high risk of HIV transmission in sperm donation. 105 The Committee was forced
to make a decision about the exclusion based on a study that exaggerated the rate of
communicable diseases among MSMs. 106
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The sources used by the FDA to support its exclusion illustrate a weak link between the rates
of HIV transmission in sperm donation and the rate of transmission among anonymous MSM
sperm donors. 107 The CDC Report's only refers to four instances ofHIV transmission in sperm
donation; however, none of the instances involve the sperm collected through the FDA mandated
testing provisions.

108

The Advisory Committee Meeting transcript demonstrates that the

committee itself questioned whether the available data accurately illustrated the threat posed by
anonymous MSM sperm donation. 109 Neither the CDC Report nor the Advisory Committee
Meeting provides evidence strong enough to justify the FDA's exclusion ofMSMs.

IV.RAISING A CONSTITUTIONAL CHALLENGE TO THE EXCLUSION UNDER
THE EQUAL PROTECTION CLAUSE.
By relying on unconvincing sources, the FDA's exclusion raises public policy issues about
the govermnent's treatment of the LGBT community. 110 It stunts the LGBT movement, by
perpetuating discriminatory behaviors upon the LGBT community. The exclusion requires gay
men to either change their behavior or suppress their sexual identity from the general
population. 111 A constitutional challenge to the exclusion can be raised under the Equal
Protection Clause of the Fourteenth Amendment. 112 It places an additional burden on gay men,
without placing similar requirements on sexually active heterosexual males. 113 Additionally, it
does not advance a legitimate state interest of protecting the public health, because the mandated
testing period satisfies that state interest. 114

a. The Exclusion Perpetuates the Discriminatory Behavior of "Gay Passing" and "Gay
Covering"
107
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The exclusion perpetuates the discriminatory behaviors of "gay passing" and "gay covering"
upon the LGBT community. 115 Chief Justice Earl Warren Professor of Constitutional Law Kenji
Yoshino highlights the types of discrimination the LGBT community faces in society through an
analysis of three distinct forms of inequality: "gay conversion," "gay passing," and "gay
covering." 116 Gay conversion requires a homosexual to convert their sexual identity, while "gay
passing" merely asks a homosexual person to hide their identity. 117 However, "gay covering"
does not require a homosexual to hide their identity, but to downplay it. 118 The government has
implemented these inequalities in a variety of legislation. 119 The exclusion on MSMs is no
exception; it perpetuates "gay passing" and "gay covering" by requiring MSMs to either hide or
. 120
. sexuaI 1.dentity.
downpIay th e1r
In the social context, "gay passing" is where society requires homosexuals to hide their
sexual identity rather than convert it. 121 In other words, "[p ]assing is acting straight by feigning
an interest in sports, by creating a fictitious girlfriend, [or] by laughing at the right jokes." 122
Passing, unlike conversion, occurs in a selective manner; an individual is faced with many
closets to come out from and can choose to come out or pass given their level of comfort, i.e.
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Kenji Yoshino, supra note 110, at 775.
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mId at 772.
liS Id
9
II The United States Military is an excellent illustration of the Government's move from a "gay conversion" policy to a
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homosexuals can choose to come out to their friends, parents, co-workers, bosses or choose to
remain hidden from all or some of these parties. 123
In the legal context, the state and federal government enforced certain legislations that
encouraged the LGBT community to hide their identity. 124 The 1993, "don't ask, don't tell
policy" (hereinafter "DADT") was a "gay passing" legislation. 125 It required LGBT members
serving in the military to hide their sexual identity, and if their identity was revealed during
service, they were automatically discharged. 126 Under DADT, the number of exclusions of
homosexual men from service far exceeded the exclusion of homosexual men from the military's
previous "gay conversion" policy of requiring homosexuals to convert to heterosexuality in order
to serve. 127
Just like the DADT, the FDA's exclusion on MSMs encourages "gay passing" among
MSMs. The FDA regulation requires interviewers to ask potential donors about their medical and
sexual history. 128 Through this process, the interviewer can learn whether a potential donor
belongs to the MSM subgroup, and therefore is ineligible to anonymously donate sperm. 129
Because the guidance document excludes MSMs from anonymously donating sperm, MSMs
would be more inclined to hide their sexual identity during the interview process. 130 An MSM
could anonymously donate sperm, as long as he did not reveal his sexual identity to the sperm

Id
ld at 827.
12s Id
126
!d at 827-28 (citing JANET E. HALLEY, DON'T: A READER'S GUIDE TO MILITARY'S ANTI-GAY POLICY 33 (1999); 10
u.s.c.
§ 654(b)(l), (3) (1994)).
127
!d at 833 (citing OFFICE OF UNDER SEc'Y OF DEF. (PERS & READINESS), REPORT TO TilE SECRETARY OF DEFENSE:
REVIEW OF TilE EFFECTIVENESS OF THE APPLICATION AND ENFORCEMENT OF TilE DEPARTMENT'S POLICY ON
HOMOSEXUAL CONDUCT IN TilE MILITARY (1998), available at http://www.defenselink.miVpubs/rot040798.html; see
also Eric Schmidt, Close Quarters: How is this Strategy Working? Don't Ask, N.Y. TIMES, Dec. 19, 1999, § 4, at 4).
128
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129
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facility; however, if his identity is discovered, then he will be subject to the exclusion. 131 The
exclusion perpetuates "gay passing" by encouraging MSMs to lie about their sexual identity, so
that they can anonymously donate sperm. 132
Along with perpetuating "gay passing," the exclusion also perpetuates "gay covering." "Gay
covering" allows homosexuals to be open about their sexuality, but requires them to downplay
it. 133 In other words, covering discourages the LGBT community from displaying homosexual
conduct in public, such as two men holding hands or kissing. 134 There are many other examples
of activities that the LGBT community engages in which are subject to covering demands. 135
Thus, covering is distinguishable from passing in that passing focuses on controlling the
visibility of homosexuality, while covering focuses on its obtrusiveness. 136
Gay covering also exists in the legal context, and has been influential in the employment of
homosexuals in the civil service and the issue of child custody and visitation between divorced
parents, where one parent is a homosexual and the other is a heterosexual. 137 In the employment
realm, there have been several cases, where the courts have held that if an openly gay
employee's sexual identity affected their employment, then there is a justifiable basis to
terminate them. 138 Regarding the custody and visitation of children, the courts have stripped
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Id.; In addition to being subject to the exclusion, the FDA enforces penalties to individuals that violate the regulation.
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custody from homosexual parents, who engage in homosexual behavior in the presence of their
children. 139
Gay covering also finds a place in the public health arena, through the FDA's exclusion. The
exclusion encourages MSMs to cover their sexual behavior. The FDA exclusion not only
punishes gay men for being open about their sexual orientation but does so based on homosexual
activity irrespective of any consideration that the specific gay man they are excluding is at a
lower risk than a straight man based on his actual sexual activity. 140 The guidance document
specifically states that "[m]en who have had sex with another man in the preceding [five] 5
years" is a risk factor for communicable diseases. 141 Conversely, the exclusion allows MSMs
who have not been sexually active for the past 5 years to anonymously donate sperm. 142
Abstaining from homosexual activity is the fundamental way in which a person can cover their
homosexuality. 143 Since the exclusion applies to sexually active MSMs, it requires MSMs to
cover their sexual identity in order to be allowed to anonymously donate sperm. 144

upheld the termination, because it was not "arbitrary or capricious" for an agency to consider pre-employment activity
when determining an person's employment eligibility.); see also Singer v. U.S. Civil Serv. Comm'n, 530 F.2d 247 (9th
Cir. 1976) (Singer, an openly gay clerk typist for the EEOC was terminated for openly professing his sexuality in the
workplace, the Ninth Circuit upheld the termination stating that Singer was "openly and publicly flaunting his
homosexual way of life and indicating further continuance of such activities, while identifYing himself as a member of a
federal agency.").
139
See generally Chaffm v. Frye, 45 Cal. App.3d 39 (Ct. App. 1975) (The California Court of Appeal denied custody
and visitation rights to a lesbian mother, stating that she was engaged in homosexual conduct with another woman and
intended to raise her child in that environment); see also Scott v. Scott, 665 So.2d 760 (La. App. 1 Cir. 1995) (The
Louisiana Court of Appeal denied custody to a lesbian mother, after hearing from several witnesses about her public
display of affection with another woman that extended beyond what the court considered affection accepted between two
women); and In re J.S. & C., 324 A.2d 90 (N.J. Super. Ct. Ch. Div. 1974), aff'd, 362 A.2d 54 (N.J. Super. Ct. App. Div.
1976) (The court granted visitation rights to a gay father under specific conditions: I) no same-sex cohabitation with
anyone aside from a legal spouse; 2) prevent children from frequenting gay establishments; and 3) prevent children from
p,artaking in homosexual advocacy or publicity.).
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In addition to requmng MSMs to cover by refraining from homosexual activity, the
exclusion also requires sexually active MSMs to behave in a certain way. 145 Although the
regulation excludes MSMs from anonymously donating sperm, it allows them to make directed
donations. 146 The FDA rationalizes that a recipient of a directed donation would select an MSM
who is free of any communicable diseases. 147 Both the exclusion and the regulation require
MSMs interested in donating sperm to do so only through a directed donation. 148 This is similar
to the courts requiring homosexual parents to behave in a specific way in order to preserve their
custody and visitation rights. 149 Therefore, the exclusion and the regulation perpetuates gay
covering on the LGBT community by either encouraging them to refrain from homosexual
activity or behave in a specific way, i.e. to only make directed donations. 150
The government has passed various laws and regulations that have perpetuated three forms of
inequality against the LGBT community: "gay conversion," which required people to convert to
heterosexuality; "gay passing," which required them to hide their sexuality, and finally "gay
covering," which required them to downplay their sexuality. 151 The FDA exclusion continues
this government tradition, by perpetuating "gay passing" and "gay covering" inequalities against
the LGBT community. 152 The exclusion increases the propensity of MSMs to hide their sexual
identity in order to anonymously donate sperm. 153 In addition, the exclusion also requires MSMs
open about their sexuality, to either refrain from engaging in homosexual activity, or behaving in
a specific way. 154

145

FDA Regulation, supra note 2.
Id
147 Id
148
Jd; Draft Guidance Document, supra note 4, at 14.
149
Kenji Yoshino, supra note 110, at 858-63.
15
°FDA Regulation, supra note 2; see also Draft Guidance Document, supra note 4, at 14.
151
Kenji Yoshino, supra note 110, at 772-75.
152
FDA Regulation, supra note 2; Draft Guidance Document, supra note 4, at 14.
153
Draft Guidance Document, supra note 4, at 14.
154
!d.; see also FDA Regulation, supra note 2.
146

22

b. The Constitutional Challenges to the Exclusion ofMSMs

Not only does the exclusion lack a reasonable justification and perpetuate discriminatory
behavior, it also raises a constitutional issue under the Equal Protection Clause of the Fourteenth
Amendment. 155 The exclusion violates the clause by placing a restriction on MSMs interested in
anonymously donating sperm. 156 In addition, the exclusion fails the equal protection clause's
rational basis test, because it does not satisfy a legitimate state interest, i.e. protecting the public
from communicable diseases. 157
For many years, the judicial system has played a balancing game between respecting the
government's power to implement legislation, with protecting individual liberties. Skinner v.
Oklahoma is a perfect example of the Court preserving individual liberties over the

government's attempts to maintain imprudent legislation.

158

The case dealt with the

constitutionality of Oklahoma's "Habitual Criminal Sterilization Act," which stated that a
"habitual criminal," a person convicted oftwo or more crimes involving "moral turpitude," could
be rendered sexually sterile through a decision of a court or a jury, so long as the sterilization
does not jeopardize their general health. 159 The sterilization can be administered by a vasectomy
for a man or a salpingectomy for a woman. 160 The statute also indicated that individuals who
committed "prohibitory laws, revenue acts, embezzlement, or political offenses" did not commit
crimes involving "moral turpitude." 161
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The case arose after petitioner, Jack T. Skinner, ("Skinner") was ordered to be sterilized after
committing three offenses that the Oklahoma court considered to involve "moral turpitude." 162
Skinner challenged the constitutionality of the statute under the equal protection clause of the
Fourteenth Amendment, and the Supreme Court of the United States held that the statute violated
the equal protections clause, because it did not apply to all offenses equally. 163
The Court applied the strict scrutiny test to the statute arguing that it involved one of the
basic civil rights of man, marriage and procreation.

164

Under a strict scrutiny test, the

government needed to show a compelling state interest in maintaining the challenged statute that
interfered with an individual's liberties. 165 The Court did not find a compelling state interest in
the Oklahoma statute and held it unconstitutional. 166 In his reasoning, Justice Douglas stated that
"the power to sterilize, if exercised, may have subtle, far-reaching and devastating effects." 167
Skinner v. Oklahoma is the first instance where the Supreme Court recognizes the right to

procreation as a fundamental right that is protected under the equal protection clause. 168 Just like
the Oklahoma statute, the exclusion prohibits MSMs from their right to procreate. 169 For many
gay men, fatherhood is limited to artificial insemination and sperm donation, but this exclusion
limits this right. 170
Although the draft guidance document considers MSMs from anonymously donating sperm
as a risk factor; it does not consider men who have unprotected sex with multiple women as a
162
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risk factor that requires exclusion. 171 In fact, the document is silent about the sexual activity of
heterosexual males. 172 It "lays an unequal hand on those who have committed" the same act as
others and "has made an invidious discrimination as if it had selected a particular race or
nationality for oppressive treatment." 173 Just like the Oklahoma statute unfairly applied to
identical offenders, the draft guidance document restricts one group from anonymously donating
sperm because of their sexual activity, while remaining silent about whether the sexual activity
of another group constitutes a risk factor. 174 Thus, under the Court's holding in Skinner, the
. vw
. Iates the equa! protectiOn
. cI ause. 175
excIuswn

The United States Supreme Court in Skinner applied a strict scrutiny test, which the Court
has declined to extend to the LGBT community. 176 Instead, the Court has recognized that a
statute restricting the rights of the LGBT community must satisfy a rational basis test. 177 In the
1996 case, Romer v. Evans, the Court held that an amendment to the Colorado statute restricting
the rights of the LGBT community violated the equal protection clause under a rational basis

The case arose after the Colorado legislature amended the constitution to prohibit any special
protected status to the LGBT community that might be implemented through state laws or
municipal ordinances. 179 The Court analyzed the amendment to the Colorado constitution and
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held that the amendment barred the LGBT community from necessary legal protections in
various areas including, real estate, housing, insurance, health, welfare, etc. 180 The Court applied
the equal protection clause under a rational basis test, instead of the strict scrutiny test, because
the LGBT community did not constitute a suspect class. 181 Under a rational basis test, the
amendment failed to advance a legitimate state interest, and imposed "a broad and
undifferentiated disability on a single named group. 182 Therefore the Court held the amendment
to the Colorado was unconstitutional. 183
Even though Romer limits the LGBT community to a rational basis analysis, the exclusion is
still invalid under the equal protection clause because it fails to advance the legitimate state
interest of protecting the public from the risk of communicable diseases. 184 The impact of the
exclusion is defused by the strict testing and quarantine requirements associated with sperm
donations. 185 The 6 month quarantine period ensures that the risk of communicable diseases in a
sperm donation is significantly reduced. 186 There is no legitimate state interest that is advanced
by excluding MSMs, because the state's interest is sufficiently met through the testing and
quarantine procedures. 187 Therefore under Romer, the exclusion is invalid under a rational basis
review of the equal protection clause, because "if the constitutional conception of 'equal
protection of the laws' means anything, it must at the very least mean that a bare ... desire to harm
a politically unpopular group cannot constitute a legitimate governmental interest." 188
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The FDA exclusion on MSMs from anonymously donating sperm places a cumbersome
restriction on the LGBT community. 189 It perpetuates the discriminatory practices of "gay
passing" and "gay covering." 190 It requires MSMs to hide their sexual identity, refrain from
homosexual activity, or behave in a specific way by making directed sperm donations. 191 The
exclusion also violates the equal protection clause of the fourteenth amendment. 192 It applies an
additional restriction on MSMs, while posing no similar restriction on promiscuous heterosexual
males. 193 The exclusion does more harm than good to the public health arena; therefore, the
guidance document and regulation must be amended and the exclusion must be removed.
V. THE CASE FOR AMENDING THE GOVERNING FDA REGULATION.

The FDA exclusion serves no actual purpose in protecting the public health from the risk of
communicable diseases, and should therefore be removed from the guidance document and the
FDA regulation. 194 Although the FDA's initial intent in creating this exclusion has been to
protect the public health, it effectively deprives the LGBT community from enjoying equal
treatrnent. 195 The regulation and guidance document must be amended and the exclusion must be
removed in order to promote the equal treatment of the LGBT community in the public health
community.

a. The FDA Regulation and Guidance Document Must Be Amended to Remove the
Exclusion and Adopt the Alternative Method Advocated by Lambda Legal Defense
Education Fund.
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Since the implementation of the FDA regulation in May 2005, some groups have actively
attempted to change the regulation and remove the exclusion. 196 The Lambda Legal Defense and
Education Fund 197 (hereinafter "LLDEF") has written and sent a letter to the FDA voicing their
disapproval towards the exclusion. 198 In their letter, LLDEF suggests an alternative method of
protecting the public health which does not require the continued implementation of the
exclusion. 199 The FDA should adopt the LLDEF's alternative method to screen potential donors,
because it actively reduces the risk of communicable diseases without discriminating against the
LGBT community. 200
The LLDEF's letter correctly points out that the public policy concerns of protecting the
public from communicable diseases is not served by the exclusion. 201 In addition, the exclusion
lacks a foundation in science, and is made ineffective by the FDA regulation's double testing and
six-month quarantine requirement. 202 As a result of the ineffectiveness of the exclusion, the
LLDEF present an alternative method of protecting the public from the risk of communicable
diseases. 203
The LLDEF suggests the FDA should use "a more specific screening criteria that measures a
potential donor's high risk activities rather than his sexual orientation."204 The LLDEF offers up
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the HIV Medicine Association205 (hereinafter "HIVMA") of the Infectious Diseases Society of
America's 206 (hereinafter "IDSA") screening procedures as the method the FDA regulation
should adopt in its regulation to screen potential donors. 207 HIVMA recommends that the
following individuals be prohibited from donating blood or sperm:
1.
2.
3.
4.

[test] positive for HIV;
[use] illicit drugs within the previous [twelve (12)] months;
[have] a needle stick exposure to someone else's blood within the previous
12 months; or
in the previous 12 months, [have] had unprotected oral, vaginal, or anal
sexual intercourse with:
a.
An individual with HIV,
b.
An individual known to use illicit drugs, or
c.
An individual of unknown HIV status outside of a monogamous
relationship[.] 208

This screening process effectively screens potential donors and does not perpetuate a
discriminatory attitude toward the LGBT community. 209 This screening procedure also satisfies
the FDA's concerns of screening out individuals that pose a risk of transferring communicable
diseases. 210
The LLDEF's letter to the FDA provides an excellent alternative method to the one proposed
in the regulation. 211 This screening method is already used by HIVMA and IDSA, which are
dedicated to improving the medicine and procedures associated with HIV and other infectious

205
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medicine. 212 The new screening procedure satisfies the aim of the regulation, by screening out
potential donors that pose a risk of transferring communicable diseases, without unfairly
discriminating against an entire class of people. 213 The exclusion against MSMs should be
abrogated and the FDA regulation should adopt the screening procedures in use by HIVMA and
IDSA.zt4
b. The Adoption of Sperm-Washing Techniques Provides an Additional Safe-Guard to the
Risk of Communicable Diseases
If the FDA is not convinced that the LLDEF's proposed screening procedure would not
effectively identity the risk factors in potential donors, then the regulation should be amended to
require an additional safety provision. 215 Sperm-washing techniques are among the newest forms
of reducing the risk of HIV transmission in artificial insemination.Z 16 In addition to adopting the
new screening procedures, the FDA can also require each donation to go through a spermwashing procedure. 217 This will ensure the FDA's goal of protecting the public health from the
risk of communicable disease, while eliminating the discriminatory attitude toward the LGBT
community.
The sperm-washing technique allows couples where the male partner is HIV positive to
donate his sperm and impregnate his partner, without the risk of transmitting the virus. 218 It takes
the HIV infected sperm and removes the infected portion from the non-infected spermatozoa. 219
The spermatozoa are the generative components of semen and are generally not infected by the
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HIV virus. 220 The spermatozoa are then inseminated into the recipient's egg.

221

This technique

ensures that the infection is not transmitted to a recipient during artificial insemination. 222 The
FDA can require sperm washing done on all anonymous donations to ensure that the HIV virus is
almost never transmitted.

223

A study from January 2002 to January 2006 was conducted to measure the potential risk of
HIV transmission in sperm washing procedures. 224 The study surveyed 741 couples, where the
male partner was HIV positive. 225 The results showed that the rates of HIV transmission in
newborns were drastically reduced. 226 The study illustrated how sperm washing technique gave
HIV positive men the chance to biologically father a child, without the fear of transmitting the
virus. 227
As a means to placate the FDA's concern about the risk of communicable diseases in the
public health, the FDA regulation should be amended to include the sperm washing technique as
an additional preventative measure. 228 This will ensure that the goal of the FDA to protect and
promote the public health is preserved. 229 In addition, this will also encourage the FDA to
discontinue the use of discriminatory policies like the exclusion on MSMs from anonymously
230
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The exclusion does not effectively protect the public from the risk of communicable diseases;
instead, the FDA must adopt a more effective and less discriminatory procedure of screening out
potential donors.

231

The LLDEF's proposal of substituting the FDA's current screening

procedures with the ones used by HIVMA and IDSA will satisfy the FDA's concems. 232 If the
FDA is still worried about the threat of communicable diseases, it can require sperm-washing
techniques to be applied to the anonymously donated sperm. 233 This technique will significantly
reduce the risk of HIV transmission in artificial insemination. 234 These alternative methods
satisfy the mission of the FDA regulation, while refraining from discriminating against a class of
people. 235
VI. CONCLUSION

Protecting the public health from the potential dangers of various diseases is not an easy task,
and the FDA has the heavy burden to do just that. 236 For years it has developed regulations to
protect the public from the dangers associated with food, drugs, tobacco products, vaccines, and
many more. 237 Most of the FDA regulations successfully protect the public from potential
dangers; 238 however, there are those like the FDA Regulation on sperm donation that takes it too
far. 239 In its attempt to prevent the risk of communicable diseases, the FDA passes an exclusion
that overreaches and perpetuates a discriminatory attitude towards the LGBT community. 240
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As the world enters the second decade of the twenty-first century, society is becoming more
aware of the need to provide equal treatment to various groups of people, including the LGBT
community. In the past decade, there has been an increase in the number of states that have
passed marriage equality laws granting the LGBT community the right to marry. 241 Statistics
show that the younger generation of America believes that the LGBT community deserves the
same rights as other groups of people in America. 242 And on March 26th. 2013, the Supreme
Court listened to arguments in support and against the 1996 Defense of Marriage Act, which
prevents same-sex marriage from being recognized by the federal govermnent. 243 Since the
present direction is progressive treatment towards the LGBT community in the marriage arena, it
only makes sense that that should be the same direction in the public health arena. The FDA
regulation and the exclusion goes against this direction and maintains a discriminatory attitude
towards the LGBT community. 244
Although the FDA believes the exclusion against MSMs serves a functional purpose in
reducing communicable diseases, there is an alternative method that delivers the same outcome
without discriminating against an entire class of people. This method endorses the form of
screening procedures advocated by HIVMA and considers the application of sperm-washing
techniques to anonymous sperm donations. 245 The FDA's exclusion is the product of flawed
241
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research that grossly generalizes the behavior of a class of people. 246 Since its implementation,
new scientific techniques have greatly reduced the threat of communicable diseases that
undercuts the intent of the exclusion. 247 Therefore, amending the FDA regulation and removing
the exclusion serves the dual function of upholding the FDA's mission to protect the public
health, while protecting the dignity and integrity of an important community_248
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